This stock is no longer traded. It was delisted on September 18, 2026. Prices stop on that date; discussion is still counted.
Generated by AI
Summary of Sep 30's posts. Generated by AI.
Summary of Jul 16's posts. Generated by AI.
No summary yet.
No summary yet.
Investors talking about BRNS also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.
Barinthus Biotherapeutics plc American Depositary Shares is a biopharmaceutical security representing ownership in Barinthus Biotherapeutics plc, a clinical-stage company focused on immunology and inflammation. The company develops antigen-specific immunotherapeutic candidates designed to guide T cells in addressing chronic infectious diseases, autoimmune conditions, and cancer. Its current programs span therapeutic and prophylactic research in areas such as autoimmunity, inflammatory disorders, and infectious disease, reflecting a pipeline centered on immune-system modulation. Barinthus Biotherapeutics serves the biotechnology market through the development of biologic candidates intended for clinical evaluation and potential future commercialization. The American Depositary Shares provide U.S. investors with access to the company’s ordinary shares while the underlying business remains centered in the United Kingdom. Barinthus Biotherapeutics plc is headquartered in Didcot, Oxfordshire, United Kingdom.
Website20400 Century Boulevard
Germantown, MD, 20874
United States
The latest articles about BRNS.
Here is how Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) and Agilent Technologies (A) have performed compared to their sector so far this year.
Detailed price information for Barinthus Biotherapeutics Plc ADR (BRNS-Q) from The Globe and Mail including charting and trades.
Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreementScheme of arrangement expected to become effective on September 3,...